These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 29936232

  • 21. Molecular Pathogenesis of the Tauopathies.
    Götz J, Halliday G, Nisbet RM.
    Annu Rev Pathol; 2019 Jan 24; 14():239-261. PubMed ID: 30355155
    [Abstract] [Full Text] [Related]

  • 22. Transgenic Dendra2::tau expression allows in vivo monitoring of tau proteostasis in Caenorhabditis elegans.
    Han M, Saxton A, Currey H, Waldherr SM, Liachko NF, Kraemer BC.
    Dis Model Mech; 2024 Mar 01; 17(3):. PubMed ID: 38469687
    [Abstract] [Full Text] [Related]

  • 23. The role of tau (MAPT) in frontotemporal dementia and related tauopathies.
    Rademakers R, Cruts M, van Broeckhoven C.
    Hum Mutat; 2004 Oct 01; 24(4):277-95. PubMed ID: 15365985
    [Abstract] [Full Text] [Related]

  • 24. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
    Badiola N, Suárez-Calvet M, Lleó A.
    CNS Neurol Disord Drug Targets; 2010 Dec 01; 9(6):727-40. PubMed ID: 20942789
    [Abstract] [Full Text] [Related]

  • 25. Familial globular glial tauopathy linked to MAPT mutations: molecular neuropathology and seeding capacity of a prototypical mixed neuronal and glial tauopathy.
    Ferrer I, Andrés-Benito P, Zelaya MV, Aguirre MEE, Carmona M, Ausín K, Lachén-Montes M, Fernández-Irigoyen J, Santamaría E, Del Rio JA.
    Acta Neuropathol; 2020 Apr 01; 139(4):735-771. PubMed ID: 31907603
    [Abstract] [Full Text] [Related]

  • 26. Caenorhabditis elegans models of tauopathy.
    Pir GJ, Choudhary B, Mandelkow E.
    FASEB J; 2017 Dec 01; 31(12):5137-5148. PubMed ID: 29191965
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. DOPA Decarboxylase Modulates Tau Toxicity.
    Kow RL, Sikkema C, Wheeler JM, Wilkinson CW, Kraemer BC.
    Biol Psychiatry; 2018 Mar 01; 83(5):438-446. PubMed ID: 28751068
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Neuron-selective toxicity of tau peptide in a cell culture model of neurodegenerative tauopathy: essential role for aggregation in neurotoxicity.
    Zhao K, Ippolito G, Wang L, Price V, Kim MH, Cornwell G, Fulenchek S, Breen GA, Goux WJ, D'Mello SR.
    J Neurosci Res; 2010 Nov 15; 88(15):3399-413. PubMed ID: 20882568
    [Abstract] [Full Text] [Related]

  • 32. MAPT mutations associated with familial tauopathies lead to formation of conformationally distinct oligomers that have cross-seeding ability.
    Bhopatkar AA, Bhatt N, Haque MA, Xavier R, Fung L, Jerez C, Kayed R.
    Protein Sci; 2024 Sep 15; 33(9):e5099. PubMed ID: 39145409
    [Abstract] [Full Text] [Related]

  • 33. Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals.
    Chen F, David D, Ferrari A, Götz J.
    Curr Drug Targets; 2004 Aug 15; 5(6):503-15. PubMed ID: 15270197
    [Abstract] [Full Text] [Related]

  • 34. Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.
    Sahara N, Lewis J, DeTure M, McGowan E, Dickson DW, Hutton M, Yen SH.
    J Neurochem; 2002 Dec 15; 83(6):1498-508. PubMed ID: 12472903
    [Abstract] [Full Text] [Related]

  • 35. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.
    Brandt R, Hundelt M, Shahani N.
    Biochim Biophys Acta; 2005 Jan 03; 1739(2-3):331-54. PubMed ID: 15615650
    [Abstract] [Full Text] [Related]

  • 36. Potential neuroprotective strategies against tauopathy.
    Wheeler JM, Guthrie CR, Kraemer BC.
    Biochem Soc Trans; 2012 Aug 03; 40(4):656-60. PubMed ID: 22817711
    [Abstract] [Full Text] [Related]

  • 37. Human amyloid β peptide and tau co-expression impairs behavior and causes specific gene expression changes in Caenorhabditis elegans.
    Wang C, Saar V, Leung KL, Chen L, Wong G.
    Neurobiol Dis; 2018 Jan 03; 109(Pt A):88-101. PubMed ID: 28982592
    [Abstract] [Full Text] [Related]

  • 38. Different tau species lead to heterogeneous tau pathology propagation and misfolding.
    Dujardin S, Bégard S, Caillierez R, Lachaud C, Carrier S, Lieger S, Gonzalez JA, Deramecourt V, Déglon N, Maurage CA, Frosch MP, Hyman BT, Colin M, Buée L.
    Acta Neuropathol Commun; 2018 Nov 29; 6(1):132. PubMed ID: 30497516
    [Abstract] [Full Text] [Related]

  • 39. Diverse, evolving conformer populations drive distinct phenotypes in frontotemporal lobar degeneration caused by the same MAPT-P301L mutation.
    Daude N, Kim C, Kang SG, Eskandari-Sedighi G, Haldiman T, Yang J, Fleck SC, Gomez-Cardona E, Han ZZ, Borrego-Ecija S, Wohlgemuth S, Julien O, Wille H, Molina-Porcel L, Gelpi E, Safar JG, Westaway D.
    Acta Neuropathol; 2020 Jun 29; 139(6):1045-1070. PubMed ID: 32219515
    [Abstract] [Full Text] [Related]

  • 40. Transgenic animal models of tauopathies.
    Lee VM, Kenyon TK, Trojanowski JQ.
    Biochim Biophys Acta; 2005 Jan 03; 1739(2-3):251-9. PubMed ID: 15615643
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.